nyuuzyou/wikis huggingface dataset:
Tucatinib (Tukysa)

==Mechanism of action==
From the NCI Drug Dictionary: An orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity. Tucatinib selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells. 
==Diseases for which it is established==
*HER2+ breast cancer
==Diseases for which it is used==
*HER2+ colorectal cancer
==History of changes in FDA indication==
*2020-04-17: Initial approval in combination with trastuzumab and capecitabine, for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Based on HER2CLIMB)
*2023-01-19: Granted accelerated approval in combination with trastuzumab for RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Based on MOUNTAINEER)
==History of changes in EMA indication==
*2021-02-11: Initial marketing authorization as Tukysa.
==Also known as==
*Code name: ARRY-380, ONT-380
*Generic name: irbinitinib
*Brand name: Tukysa
Category:Drugs
Category:Oral medications
Category:Protein expression-specific medications
Category:ERBB2 inhibitors
Category:Breast cancer medications
Category:Colorectal cancer medications
Category:EMA approved in 2021
Category:FDA approved in 2020
Tufts Medical Center Hematology Oncology Fellowship

For information about other programs, please visit the Hematology Oncology Fellowship Programs Directory.
People affiliated with this program are cordially invited to add additional information.
"Tufts Medical Center’s Hematology/Oncology Fellowship Program is an ACGME accredited program that provides training in all aspects of hematology and oncology. The Division of Hematology and Oncology emphasizes clinical instruction and research training in an academic environment."
==Basic information==
Name: Tufts Medical Center Hematology Oncology Fellowship
Fellowship program website: https://www.tuftsmedicalcenter.org/patient-care-services/Departments-and-Services/Cancer-Center/Training-Education.aspx
ACGME ID: 1552412029
===Leadership===
*Program Director: Rachel Buchsbaum, MD
===Fellowship Coordinator===
Melissa Reardon
Tufts Medical Center
800 Washington St. Box 245
Boston, MA 02111
Phone: 617-636-2523
Fax: 617-636-8538
Email: mreardon@tuftsmedicalcenter.org
==Application process and requirements==
https://www.tuftsmedicalcenter.org/patient-care-services/Departments-and-Services/Cancer-Center/Training-Education.aspx
===Process===
*Applications accepted starting on: 
*Application deadline: 
*Applications submitted through ERAS
===Requirements===
*Three letters of recommendation, one must be from current residency program
*Board scores
*Personal statement
==Statistics==
*Number of fellowship positions available per year: 
*Board certification eligibility upon fellowship completion: Hematology and Oncology
*Length of fellowship: 3 years
==Schedule==
===Year 1===
"The first year of the program is devoted to clinical training in Hematology and Oncology within a comprehensive ambulatory setting."
===Year 2===
"The second and third years emphasize research training, along with a continuation of specialty clinical work, including bone marrow transplantation and in-patient consultation services."
===Year 3===
==Affiliated medical facilities==
*Tufts Medical Center
*Lahey Clinic
==Testimonials==
Testimonials from fellows are welcome. If you are a current or former fellow and would be willing to answer questions from applicants, please tell us and sign up for a free account so you can be listed here. Your email address will not be shared--messages will be sent through the site directly to the email address you provide us.
==Notable faculty==
To be listed by fellowship program.
Category:Hematology & Oncology fellowship programs
Tumor markers

Is there information missing from this list? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
==5-HIAA (5-hydroxy-indol acetic acid)==
==AFP (alpha-fetoprotein)==
==B2M (beta-2 microglobulin)==
==BCR/ABL==
==Beta-hCG (beta-human chorionic gonadotropin)==
==CA-125 (cancer antigen 125 or carbohydrate antigen 125)==
==CA 15-3 (cancer antigen 15-3 or carbohydrate antigen 15-3)==
==CA 19-9 (cancer antigen 19-9 or carbohydrate antigen 19-9)==
==CA 27.29 (cancer antigen 27.29 or carbohydrate antigen 27.29)==
==Calcitonin==
==CEA (carcinoembryonic antigen)==
==Chromogranin A (CgA)==
==LDH==
==PSA (prostate specific antigen)==
==Tg (thyroglobulin)==
Category:General reference pages
Tunlametinib (HL-085)

==Mechanism of action==
MEK inhibitor
==History of changes in NMPA indication==
*2024-03-18: Approved for the treatment of patients with advanced melanoma harboring NRAS mutations who were previously treated with anti–PD-1/PD-L1 therapy. (Based on HL-085-101-II)
==Also known as==
*Code name: HL-085
Category:Drugs
Category:Oral medications
Category:MEK inhibitors
Category:Melanoma medications
Category:NMPA approved in 2024
Category:Stub
UCLA Medical Center Hematology Oncology Fellowship

For information about other programs, please visit the Hematology Oncology Fellowship Programs Directory.
People affiliated with this program are cordially invited to add additional information.
"The objective of the UCLA combined Hematology and Oncology training program is to provide trainees with the necessary skills to be astute clinicians, educators, and future leaders in clinical, health policy, or basic science and translational research."
==Basic information==
Name: UCLA Medical Center Hematology Oncology Fellowship
Fellowship program website: https://www.hemonc.med.ucla.edu/index.html
ACGME ID: 1550521123
===Leadership===
*Program Director: Sarah Larson, MD
===Fellowship Coordinator===
CJ Cabrera
UCLA Division of Hematology-Oncology
10945 Le Conte Ave. Ste 2333
Los Angeles, CA 90095
Email: cjcabrera@mednet.ucla.edu
Phone: (310) 206-1214
Fax: (310) 206-3289
==Application process and requirements==
https://www.hemonc.med.ucla.edu/applicants.html
===Process===
*Applications accepted starting on: 
*Application deadline: 
*Applications submitted through ERAS
===Requirements===
*US Citizen or US Permanent Resident (does not accept J1 and H1B applicants)
*Completed at least 1.5 years of US ACGME-accredited residency training at the time of application
*Passed UCMLE step 1 & 2
*"Hold a current and valid California Medical License or, in lieu of a California Medical License, applied for a Postgraduate Training Authorization Letter (PTAL) through the California Medical Board if you have not received residency training in the United States. If a PTAL is required, you must one by the time interviews are concluded in order to be eligible to submit your name in the ranking. Please note that the PTAL takes approximately 60-90 days to receive so please apply early in the ERAS application process. If you have received residency training in the United States through an ACGME-accredited program, there should be no requirement for a PTAL."
==Statistics==
*Number of fellowship positions available per year: 4 to 6 (one position is a geriatric-oncology slot and is not placed in the match)
*Over 200 applicants apply each year; about 70 candidates interviewed
*Board certification eligibility upon fellowship completion: Hematology and Oncology or geriatric medicine/oncology
*"Together with the UCLA Division of Geriatrics, the UCLA Division of Hematology/Oncology also offers a combined 3-year geriatrics and oncology fellowship program."
*Length of fellowship: 3 years
==Schedule==
https://www.hemonc.med.ucla.edu/curriculum.html
===Year 1===
===Year 2===
===Year 3===
==Affiliated medical facilities==
*Ronald Reagan UCLA Medical Center
==Testimonials==
Testimonials from fellows are welcome. If you are a current or former fellow and would be willing to answer questions from applicants, please tell us and sign up for a free account so you can be listed here. Your email address will not be shared--messages will be sent through the site directly to the email address you provide us.
==Notable faculty==
To be listed by fellowship program.
Category:Hematology & Oncology fellowship programs
Ublituximab (Briumvi)

==Mechanism of action==
From the NCI Drug Dictionary: A chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ublituximab specifically binds to the B cell-specific cell surface antigen CD20, thereby potentially inducing a B cell-directed complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells, leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development and is often overexpressed in B-cell malignancies. Ublituximab has a specific glycosylation profile, with a low fucose content, that may enhance its ADCC response against malignant B cells.
==Diseases for which it is used==
*CLL
==History of changes in FDA indication==
No antineoplastic indication, at this time.
*2023-01-06: Approved for the treatment of relapsing multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
==Also known as==
*Code names: LFB-R603, TG-20, TG-1101, TGTX-1101
*Generic name: ublituximab-xiiy
*Brand name: Briumvi
Category:Drugs
Category:Intravenous medications
Category:Anti-CD20 antibodies
Category:Chronic lymphocytic leukemia medications
Category:FDA approved in 2023
Umbralisib (Ukoniq)

==Mechanism of action==
Phosphatidylinositol 3-kinase (PI3K) isoform p110δ (PI3Kδ) and casein kinase-1ε inhibitor
==Diseases for which it was used==
*Follicular lymphoma
*Marginal zone lymphoma
== Patient Drug Information==
*Umbralisib (Ukoniq) Package InsertUmbralisib (Ukoniq) Package Insert
==History of changes in FDA indication==
*2021-02-05: Accelerated approval for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen. (Based on UNITY-NHL)
**2022-06-01: Accelerated approval withdrawn due to safety concerns. (Based on UNITY-CLL)
*2021-02-05: Accelerated approval for adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy. (Based on UNITY-NHL)
**2022-06-01: Accelerated approval withdrawn due to safety concerns. (Based on UNITY-CLL)
==Also known as==
*Code name: TGR-1202
*Brand name: Ukoniq
==References==
Category:Drugs
Category:Oral medications
Category:PI3K delta inhibitors
Category:CK1 epsilon inhibitors
Category:Follicular lymphoma medications (historic)
Category:Marginal zone lymphoma medications (historic)
Category:FDA approved in 2021
Category:Discontinued drugs
Category:FDA withdrawn in 2022
Category:TG Therapeutics compound
Unfractionated heparin (UFH)

==General information==
Class/mechanism: Acts at multiple points in the coagulation cascade to inhibit clotting and the formation of fibrin clots. Heparin interacts with antithrombin III (AT-III), inactivates the conversion of prothrombin to thrombin, inactivates thrombin and its effect of catalyzing the formation of fibrin from fibrinogen, and inhibits the activation of fibrin-stabilizing factor.Heparin package insert Heparin package insert (locally hosted backup)Heparin manufacturer's website
Route: IV, SC
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Patient drug information==
*Brief patient counseling information can be found in the Heparin package insert
*Heparin patient drug information (UpToDate)Heparin patient drug information (UpToDate)
==Also known as==
*Generic name: UFH
==References==
Category:Drugs
Category:Intravenous medications
Category:Subcutaneous medications
Category:Anticoagulants
Category:Heparins
Category:Venous thromboembolism medications
Category:FDA approved in 1939
University of Arizona Hematology Oncology Fellowship

For information about other programs, please visit the Hematology Oncology Fellowship Programs Directory.
People affiliated with this program are cordially invited to add additional information.
"Fellows obtain extensive clinical experience and have an opportunity for in-depth study in clinical, basic or translational research. The combination of training in patient care and research provides physicians with strong clinical skills and the foundation for a successful career in academics, industry, or clinical practice."
==Basic information==
Name: University of Arizona Hematology Oncology Fellowship
Fellowship program website: https://cancercenter.arizona.edu/outreach-and-education/education-training/postdocs-fellows/hematology-and-medical-oncology
ACGME ID: 1550321003
===Leadership===
*Program Director: Pavani Chalasani, MD, MPH
===Fellowship Coordinator===
Imelda Galvan
Division of Hematology & Oncology
Univ of Arizona Coll of Med-Tucson
Rm 1969G
1515 N Campbell Ave
Tucson, AZ 85724
Email: igalvan@uacc.arizona.edu 
Telephone: (520) 626-8096
==Application process and requirements==
https://cancercenter.arizona.edu/outreach-and-education/education-training/postdocs-fellows/hematology-and-medical-oncology
===Process===
*Applications accepted starting on: 
*Application deadline: 
*Applications submitted through ERAS
*Interviews take place in August and September. Interview requests are sent to applicants' e-mails listed in ERAS
===Requirements===
*Three letters of recommendation; one must be from internal medicine residency Program Director
*Copy of medical school transcript
*Copy of the Dean's letter. 
*International medical graduates must have a Standard Certificate of the Educational Commission for Foreign Medical Graduates (ECFMG)
*University of Arizona accepts J-1 and will occasionally H-1B visas. 
==Statistics==
*Number of fellowship positions available per year: 4
*Board certification eligibility upon fellowship completion: Hematology and Oncology
*Length of fellowship: 3 years
==Schedule==
===Year 1===
===Year 2===
===Year 3===
==Affiliated medical facilities==
* Banner Health 
* Southern Arizona VA 
==Testimonials==
Testimonials from fellows are welcome. If you are a current or former fellow and would be willing to answer questions from applicants, please tell us and sign up for a free account so you can be listed here. Your email address will not be shared--messages will be sent through the site directly to the email address you provide us.
==Notable faculty==
To be listed by fellowship program.
Category:Hematology & Oncology fellowship programs
University of California (Irvine) Hematology Oncology Fellowship

For information about other programs, please visit the Hematology Oncology Fellowship Programs Directory.
People affiliated with this program are cordially invited to add additional information.
"The Division of Hematology/Oncology at UC Irvine's School of Medicine offers a rigorous three-year accredited fellowship program that emphasizes intensive theoretical training and a broad spectrum of clinical experience with the goal of preparing highly skilled hematologists and oncologists for careers in both clinical and academic medicine."
==Basic information==
Name: University of California (Irvine) Hematology Oncology Fellowship
Fellowship program website: https://www.medicine.uci.edu/hematology/fellowship.asp
ACGME ID: 1550521136
===Leadership===
*Program Director: Dr. Jason Zell
*Associate Program Director: Dr. Chaitali Nangia
*Division Chief: Dr. Edward Nelson
===Fellowship Coordinator===
Kathryn Kennedy
Phone: 714-456-6589 or 714-456-5153
Fax: 714-456-2242
Email: kennedy@uci.edu
General: 
The Division of Hematology/Oncology
UC Irvine Medical Center
101 The City Drive South
Building 56, Route 81, Room #246V
Orange, CA 92868
==Application process and requirements==
https://www.medicine.uci.edu/hematology/fellowship.asp
===Process===
*Applications accepted starting on: 
*Application deadline: 
*Applications submitted through ERAS
===Requirements===
*U.S. citizen, U.S. permanent resident, or have a J-1 visa with ECFMG sponsorship
*Completed three-year residency program in an Internal Medicine program recognized by ACGME and the ABIM. 
*"Applicants also should be able to demonstrate their interest in the subspecialties of hematology and oncology."
*Will need to have valid California medical license before beginning the fellowship program
==Statistics==
*Number of fellowship positions available per year: 
*Board certification eligibility upon fellowship completion: Hematology and Oncology
*Length of fellowship: 3 years
==Schedule==
https://www.medicine.uci.edu/hematology/fellowship.asp
===Year 1===
===Year 2===
===Year 3===
==Affiliated medical facilities==
*UC Irvine Chao Family Comprehensive Cancer Center
*UC Irvine Medical Center
*VA Long Beach Healthcare System
==Testimonials==
Testimonials from fellows are welcome. If you are a current or former fellow and would be willing to answer questions from applicants, please tell us and sign up for a free account so you can be listed here. Your email address will not be shared--messages will be sent through the site directly to the email address you provide us.
==Notable faculty==
To be listed by fellowship program.
*Dr. Rita Mehta
*Dr. Tara Seery
Category:Hematology & Oncology fellowship programs
University of California (San Diego) Hematology Oncology Fellowship

For information about other programs, please visit the Hematology Oncology Fellowship Programs Directory.
People affiliated with this program are cordially invited to add additional information.
"The Hematology-Oncology Fellowship Training Program at UC San Diego is a fully integrated program including hematology, oncology, and bone marrow transplantation. It is 3 years in duration and is designed to prepare Fellows for careers in the academic field of their choice."
==Basic information==
Name: University of California (San Diego) Hematology Oncology Fellowship
Fellowship program website: https://healthsciences.ucsd.edu/som/medicine/divisions/hem-onc/education-training/fellowship-program/Pages/default.aspx
ACGME ID: 1550512007
===Leadership===
*Program Director: Sanford J. Shattil, MD
===Fellowship Coordinator===
Susan Stafford
Program Coordinator
Phone: 858-657-5281
Fax: 858-657-5348
Email: sustafford@ucsd.edu
==Application process and requirements==
https://healthsciences.ucsd.edu/som/medicine/divisions/hem-onc/education-training/fellowship-program/Pages/apply.aspx
===Process===
*Applications accepted starting on: 
*Application deadline: 
*Applications submitted through ERAS
*Interviews in October
===Requirements===
*U.S. Citizens and U.S. Permanent Residents
*Completed application
*Personal Statement
*Curriculum Vitae (CV)
*Three letters of recommendation; one must be from current Program Director
*Medical School transcripts, USMLE transcripts, and Dean’s letter
==Statistics==
*Number of fellowship positions available per year: 4
*Board certification eligibility upon fellowship completion: Hematology and Oncology
*Length of fellowship: 3 years
==Schedule==
Sample rotation schedule for a first and second year fellow
===Year 1===
===Year 2===
===Year 3===
==Affiliated medical facilities==
https://healthsciences.ucsd.edu/som/medicine/divisions/hem-onc/education-training/fellowship-program/Pages/Clinical-Training.aspx
https://healthsciences.ucsd.edu/som/medicine/divisions/hem-onc/education-training/Pages/clinical-sites.aspx
*UC San Diego Moores Cancer Center
*UC San Diego Hospital at Hillcrest, San Diego
*John M. and Sally B. Thornton Hospital, La Jolla
*VA San Diego Healthcare System, La Jolla
*Owen Clinic
*Sulpizio Family Cardiovascular Center (CVC)
==Testimonials==
Testimonials from fellows are welcome. If you are a current or former fellow and would be willing to answer questions from applicants, please tell us and sign up for a free account so you can be listed here. Your email address will not be shared--messages will be sent through the site directly to the email address you provide us.
==Notable faculty==
To be listed by fellowship program.
Category:Hematology & Oncology fellowship programs
University of California (San Francisco)/Fresno Hematology Oncology Fellowship

For information about other programs, please visit the Hematology Oncology Fellowship Programs Directory.
People affiliated with this program are cordially invited to add additional information.
"The goal of the UCSF Fresno Hematology Oncology Fellowship Program is that graduates will attain the professional, attitudinal, cognitive, and technical skills necessary to provide their patients with kind and compassionate care."
==Basic information==
Name: University of California (San Francisco)/Fresno Hematology Oncology Fellowship
Fellowship program website: https://www.fresno.ucsf.edu/internal/hema_onc/
ACGME ID: 1550514164
===Leadership===
*Program Director: Uzair Chaudhary, MD
===Fellowship Coordinator===
Ana Zarate 
2335 E. Kashian Lane
Suite 301 
Fresno, CA 93701
Phone: (559) 459-6525
Fax: (559) 459-6395
Email: hemonc@fresno.ucsf.edu
==Application process and requirements==
https://www.fresno.ucsf.edu/internal/hema_onc/application.html
===Process===
*Applications accepted starting on: 
*Application deadline: 
*Applications submitted through ERAS
===Requirements===
*U.S. Citizens, U.S. Permanent Residents, EAD (work permit), ECFMG-sponsored J-1 visa. "The University does not sponsor H-1B visas. Please contact individual programs regarding their policy on sponsoring H-1B visas."
*Application
*Personal statement
*Curriculum Vitae (CV)
*Three letters of recommendation
*Medical school transcripts
*USMLE transcripts
*ECFMG certificate (if applicable)
*California Medical License
==Statistics==
*Number of fellowship positions available per year: 2
*Board certification eligibility upon fellowship completion: Hematology and Oncology
*Length of fellowship: 3 years
==Schedule==
===Year 1===
===Year 2===
===Year 3===
==Affiliated medical facilities==
*Community Regional Medical Center
==Testimonials==
Testimonials from fellows are welcome. If you are a current or former fellow and would be willing to answer questions from applicants, please tell us and sign up for a free account so you can be listed here. Your email address will not be shared--messages will be sent through the site directly to the email address you provide us.
==Notable faculty==
To be listed by fellowship program.
Category:Hematology & Oncology fellowship programs